Cisplatinum (CDDP) and etoposide (VP16) in "poor risk" small cell lung carcinoma (SCLCA) - European Journal of Cancerdoi:10.1016/0959-8049(93)91496-8Casadio, M.Marioni, A.Melotti, B.Ramini, R.Pannuti, F.European Journal of Cancer...
CDDP-resistant (SBC-3/CDDP) and VP16-resistant (SBC-3/VP16) small cell lung cancer(SCLC) cells show a unique collateral sensitivity in culture : Taisuke OHNOSHI, Hiroshi UEOKA, Katsuyuki KIURA, Nagio TAKIGAWA and Ikuro KIMURA Department of Medicine, Okayama University Medical School, Okayama...
Results of Cisplatin (CDDP)/Etoposide (VP16)/5-FU and alternatively Adriamycin or Mitomycin C (PEFAM) combination in primary resistant breast cancer and in heavily pre-treated metastatic breast cancerIn spite of the activity of chemotherapeutic agents, metastatic breast cancer remains an incurable ...
Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-Fu, and VP-16 for advanced esophageal cancer. Jpn J Thorac Cardiovasc Surg. 1998;46:11-7.Mukaida H, Hirai T, Yamashita Y, Yoshida K, Hihara J, Kuwahara M, et al. Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-...
Accelerated hyperfractionated thoracic radiation therapy plus concomitant VP16-CDDP chemotherapy for unresectable stage III non-small cell lung cancerShaw, E. G.McGinnis, W.Jett, J.Su, J.LUNG CANCER -AMSTERDAM-
Response rate in advanced soft tissue sarcoma using cisplatin (CDDP), adriamycin, and VP16An abstract is unavailable. This article is available as a PDF only.doi:10.1097/00043426-199123000-00031E. G. AntoneliR. MelaragnoL. A. Marques
Concurrent platinum (CDDP)-etoposide (VP-16) chemotherapy plus thoracic radiotherapy (TRT) for limited stage small cell lung cancer (SCLC) : N. Saijo, M. Fukuoka, K. Furuse, Y. Ariyoshi, Y. Nishiwaki, H. Ikegami, M. Oritsu A Japanese Lung Cancer Chemotherapy Group (JLCCG) study, ...
Phase II trial with weekly cisplatin (CDDP) and continously oral etoposide (VP-16) in advanced non-small cell lung cancer (NSCLC) - European Journal of Cancerdoi:10.1016/0959-8049(93)91521-LLopez, R.Fernandez, R.Virizuela, J.A.
Phase II of cisplatin (CDDP), etoposide (VP16) and gemcitabine (G) in cancer of unknown primary (CUP)Clinical ResearchHuman VolunteersWomenMenstruation DisordersPituitary Hormone Releasing HormonesLuteinizing HormoneFollicle Stimulating HormoneGlucose Metabolism Effects...
CDDP (P), 5FU (F), leucovorin (L) and VP16 (PFL-VP16) in advanced non small cell lung cancer (NSCLC)The involvement of IL-6 in malignant disease has been most throughly investigated in different malignancies. To evaluate whether serum IL-6 is a useful disease marker in MMM, we ...